LAUSR

1 Talamonti M, Galluzzo M, van den Reek JM et al. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol 2017; 177:489–96. 2 Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med 1972; 287:738–40. 3 Talamonti M, Botti E, Galluzzo M et al. Presence of HLA-Cw6 but not LCE3C_LCE3B deletion influences clinical response to ustekinumab in psoriasis patients. Br J Dermatol 2011; 165:e11. 4 Li K, Huang CC, Randazzo B et al. HLA-C*06:02 allele and response to IL-12/23 inhibition: results from the ustekinumab phase 3 psoriasis program. J Invest Dermatol 2016; 136:2364–71. 5 Prieto-Perez R, Llamas-Velasco M, Cabaleiro T et al. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics 2017; 18:157–64. 6 Jorgensen A, Williamson P. Methodological quality of pharmacogenetic studies: issues of concern. Stat Med 2008; 27:6547–69. 7 Griffiths CE, Barnes MR, Burden AD et al. Establishing an academic– industrial stratified medicine consortium: psoriasis stratification to optimize relevant therapy. J Invest Dermatol 2015; 135:2903–7. 8 Warren RB, Smith CH, Yiu ZZ et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015; 135:2632–40.